Regeneron (NASDAQ:REGN) and Sanofi Get Japan Green Light for Smokers’ Lung Disease Treatment
Biotech company Regeneron (REGN) and French pharmaceutical giant Sanofi (SNY) today announced that Japan has granted ...
Pharmabiz9h
Sanofi & Regeneron’s Dupixent receives Japanese marketing approval to treat patients with COPD
Sanofi & Regeneron’s Dupixent receives Japanese marketing approval to treat patients with COPD: Paris Saturday, March 29, 2025, 09:00 Hrs [IST] The Ministry of Health, Labour an ...
Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD)
Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils ...
Fierce Biotech4d
Unity's eye treatment fails to match Eylea, though analysts still see a path forward
Unity Biotechnology’s investigational eye treatment failed to match Eylea at 20 weeks—part of the mid-stage trial’s primary ...
Fierce Biotech5d
Opthea's eye disease drug defeated by Eylea in phase 3, leaving biotech to mull future
Opthea was making preparations for the potential launch of a new eye disease drug onto the market. | A month ago, Opthea was ...
Ophthalmology Times10d
Aflibercept treat-and-extend regimen for neovascular AMD: 5-year outcomes
The investigators retrospectively evaluated 126 consecutive treatment-naïve nAMD patients (126 eyes) who received a loading ...
Yahoo Finance3d
Regeneron Pharmaceuticals, Inc. (REGN)
TARRYTOWN, N.Y., March 25, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its first quarter 2025 financial and operating results on ...